Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Apple stock received a price-target increase from JPMorgan on a favorable outlook for the company’s holiday-quarter sales. The post Apple Stock Scores Price-Target Hike Ahead Of Smart Home Launch appeared first on Investor’s Business Daily.
Veeva stock is Monday’s IBD Stock Of The Day. Shares tested a flat base after a solid fiscal second-quarter report. The post IBD Stock Of The Day Veeva Flirts With A Breakout. Can It Catch Up To Salesforce? appeared first…
As SharkNinja stocks swims toward a breakout to an all-time high, keep an eye on these telltale indicators. The post SharkNinja Attacks A Breakout; Senses This Technical Shift appeared first on Investor’s Business Daily.
Software leader Elastic stock is moving above an aggressive entry Monday. Shares have rallied more than 150% in just four months. The post Enterprise Software Leader Elastic Jumps Above Early Buy Point After 150% Rally In Four Months appeared first…
NHTSA regulators have started a second investigation of Tesla Cybercabs since their September launch, time time for speeding in school zones. TSLA stock edged lower. The post Tesla Cybercabs Face Regulatory Probe For Speeding In School Zones appeared first on…
Micron Technology stock slid Monday after China’s CXMT reported “key progress” on a next-generation DRAM chip. The post Micron Stock Falls On Competition From China Rival CXMT appeared first on Investor’s Business Daily.
Harmony Biosciences stock took a tumble Monday after its announced the transition of current CEO Jeffrey Dayno at the end of the year. The post Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit appeared first on…
The Tesla and SpaceX CEO is a huge donor in the midterm elections, but he’s keeping a lower profile than in 2024. The post Elon Musk Pours $276 Million Into Political Donations For Republicans In Midterms appeared first on Investor’s…
Bristol Myers Squibb scored two Phase 3 wins on Monday in lung disease and cancer. The stock rose, while a key rival plummeted. The post Bristol Myers Scores Two Phase 3 Wins, But A Key Rival Plummets On One appeared…
First Tracks Biotherapeutics posted “impressive” results for its celiac disease treatment Monday, and the IPO stock surged by double digits. The post Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed More Than 25% appeared first on Investor’s Business Daily.
